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1. Introduction 
All organisms are constantly and unavoidably exposed to xenobiotics including both man–
made and natural chemicals such as drugs, plant alkaloids, microorganism toxins, 
pollutants, pesticides, and other industrial chemicals. Formally, biotransformation of 
xenobiotics as well as endogenous compounds is subdivided into phase I and phase II 
reactions. This chapter focuses on phase II biotransformation reactions (also called 
´conjugation reactions´) which generally serve as a detoxifying step in metabolism of drugs 
and other xenobiotics as well as endogenous substrates. On the other hand, these 
conjugations also play an essential role in the toxicity of many chemicals due to the 
metabolic formation of toxic metabolites such as reactive electrophiles. Gene polymorphism 
of biotransformation enzymes may often play a role in various pathophysiological 
processes. Conjugation reactions usually involve metabolite activation by a high–energy 
intermediate and have been classified into two general types: type I (e.g., glucuronidation 
and sulfonation), in which an activated conjugating agent combines with substrate to yield 
the conjugated product, and type II (e.g., amino acid conjugation), in which the substrate is 
activated and then combined with an amino acid to yield a conjugated product (Hodgson, 
2004). In this chapter, we will concentrate on the most important conjugation reactions, 
namely glucuronide conjugation, sulfoconjugation, acetylation, amino acid conjugation, 
glutathione conjugation and methylation.  
2. Phase II reactions 
2.1 Glucuronidation 
UDP–glucuronosyltransferases (UGTs) belong among the key enzymes of metabolism of 
various exogenous as well as endogenous compounds. Conjugation reactions catalyzed by 
the superfamily of these enzymes serve as the most important detoxification pathway for 
broad spectrum of drugs, dietary chemicals, carcinogens and their oxidized metabolites, and 
other various environmental chemicals in all vertebrates. Furthermore, UGTs are involved 
in the regulation of several active endogenous compounds such as bile acids or 
hydroxysteroids due to their inactivation via glucuronidation (Miners & McMackenzie, 
1991; Kiang et al., 2005). In humans, almost 40–70% of clinically used drugs are subjected to 
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glucuronidation (Wells et al., 2004). In general, UGTs mediate the addition of UDP-hexose to 
nucleophilic atom (O–, N–, S– or C– atom) in the acceptor molecule (Mackenzie et al., 2008). 
The UDP–glucuronic acid is the most important co–substrate involved in the conjugation 
reactions (called glucuronidation) carried out by UGTs. Newly formed ǃ–D–glucuronides 
exhibit increased water–solubility and are easily eliminated from the body in urine or bile. 
The scheme of typical glucuronidation reactions is shown in Figure 1. Glucuronidation O–
linked moieties (acyl, phenolic, hydroxy) predominates the diversity in substrate 
recognition, and all of the UGTs are capable of forming O–linked glucuronides, albeit with 
different efficiencies and turn–over rates (Tukey & Strassburg, 2000). UGTs are membrane–
bound enzymes similarly to cytochromes P450 with subcellular localization in the 
endoplasmic reticulum (ER). In contrast to cytochromes P450, the active site of these 
enzymes is embedded in the lumenal part of ER. 
 
Fig. 1. Glucuronides formation. The summary of chemical structures commonly subjected to 
glucuronidation.  
2.1.1 Human forms of UGTs and their tissue distribution 
To date, the mammalian UGT gene superfamily comprises of 117 members. Four UGT 
families have been identified in humans: UGT1, UGT2 involving UGT2A and UGT2B 
subfamily, UGT3 and UGT8. Enzymes included in the UGT1 and UGT2 subfamily are 
responsible for the glucuronidation of exo– and endogenous compounds, whereas 
members of the UGT3 and UGT8 subfamilies have their distinct functions (See section 
Substrates of UGTs, inhibition, induction) (Mackenzie et al., 2008). The members of the UGT1A 
subfamily have been found to be identical in their terminal carboxyl 245 amino acids, which 
are encoded by exons 2–5. Only the uniqueness of first exon in the UGT1A subfamily genes 
differentiates one enzyme from each other. In contrast to the UGT1A subfamily, the 
members of the UGT2 gene subfamily contain a different set of exons (Tukey & Strassburg, 
2000). The UGT enzymes of each family share at least 40% homology in DNA sequence, 
whereas members of UGT subfamilies exert at least 60% identity in DNA sequence (Burchell 
et al., 1995). As of the time of writing, 22 human UGT proteins can be distinguished: 
UGT1A1, UGT1A3, UGT1A4, UGT1A5, UGT1A6, UGT1A7, UGT1A8, UGT1A9, UGT1A10, 
UGT2A1, UGT2A2, UGT2A3, UGT2B4, UGT2B7, UGT2B10, UGT2B11, UGT2B15, UGT2B17, 
UGT2B28, UGT3A1, UGT3A2, and UGT8A1 (Mackenzie et al., 2008; Miners et al., 2006; 
Court et al., 2004; Patten, 2006; Sneitz et al., 2009). In general, human UGT enzymes 
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apparently exhibit a broad tissue distribution, although the liver is the major site of 
expression for many UGTs. The UGT1A1, UGT1A3, UGT1A4, UGT1A6, UGT1A9, UGT2B7, 
and UGT2B15 belong among the main liver xenobiotic–conjugating enzymes, whereas 
UGT1A7, UGT1A8, and UGT1A10 are predominantly extrahepatic UGT forms. Moreover, 
glucuronidation activity was also detected in other tissues such as kidney (Sutherland et al., 
1993), brain (King et al.,1999), or placenta (Collier et al., 2002). 
2.1.2 UGTs substrates. Inhibition and induction of UGTs 
First of all, the fact that most xenobiotic metabolising UGTs show overlapping substrate 
specificities should be noted. Two UGTs, namely UGT8A1 and UGT3A1, stand apart from 
other UGT enzymes since they possess specific functions in the body. UGT8A1 takes part in 
the biosynthesis of glycosphingolipids, cerebrosides, and sulfatides of nerve cells (Bosio et 
al., 1996). Recently, the UGT3A1 enzyme has been shown to have a certain role in the 
metabolism of ursodeoxycholic acid used in therapy of cholestasis or gallstones (Mackenzie 
et al., 2008). Although many substrates (therapeutic drugs, environmental chemicals) are 
glucuronidated by multiple UGTs, several compounds exhibit a relative specificity towards 
individual UGT enzymes. Bilirubin is exclusively metabolised by UGT1A1 (Wang et al., 
2006). Conjugation reactions by the UGT2B7 enzyme constitute an important step in the 
metabolism of opioids (Coffman et al., 1998). Carboxylic acids including several non–
steroidal anti–inflammatory agents are conjugated mainly by UGT1A3, UGT1A4, UGT1A9, 
and UGT2B7 (Tukey & Strassburg, 2000). Acetaminophen (paracetamol) is glucuronidated 
predominantly by UGTs of the UGT1A subfamily (UGT1A1, UGT1A6, and UGT1A9) (Court 
et al., 2001). Despite the fact that in most cases UGTs are responsible for O–glucuronidation 
of their substrates, members of the UGT1A subfamily have been found to catalyze N–
glucuronidation of several amine–containing substrates (chlorpromazine, amitryptyline) 
(Tukey & Strassburg, 2000). The intestinal UGT1A8 and UGT1A10 enzymes were suggested 
to have a negative impact on the bioavailability of orally administered therapeutic drugs 
(Mizuma, 2009). For example, raloxifene, a selective estrogen receptor modulator used in 
therapy of osteoporosis, naturally has a low bioavailability and has also been shown to be 
extensively metabolised by UGT1A8 and UGT1A10 (Kemp et al., 2002). UGTs might also 
play a significant role in the inactivation of carcinogens from diet or cigarette smoke 
(Dellinger et al., 2006). Hanioka et al. (2008) proposed that the glucuronidation of bisphenol 
A (an environmental endocrine disruptor) by UGT2B15 serves as a major detoxification 
pathway of this molecule. UGTs are notably inhibited by various compounds. Analgesics, 
non–steroidal anti–inflammatory drugs (NSAIDs), anxiolytics, anticonvulsants, or antiviral 
agents have been shown to have possible inhibitory effect on the enzymatic activities of 
various UGTs (thoroughly reviewed by Kiang et al., 2005). Recently, non–steroidal anti–
inflammatory drugs have been shown to partially impair an equilibrium between biological 
functioning and degradation of aldosterone due to involvement of renal UGT2B7 in both the 
glucuronidation of aldosterone (deactivation) and the glucuronidation of NSAIDs (Knights 
et al., 2009). Similarly to other drug metabolising enzymes, UGTs are subject to induction by 
various xenobiotics or biologically active endogenous compounds (hormones) via nuclear 
receptors and transcription factors. For example, the aryl hydrocarbon receptor plays role in 
induction of UGT1A1 while the activation of pregnane X receptor and the constitutive 
androstane receptor leads to induction of UGT1A6 and UGT1A9 (Lin & Wong, 2002; 
Mackenzie et al., 2003; Xie et al., 2003). Several classes of drugs including analgesics, 
antivirals, or anticonvulsants are suspected to act as human UGTs inducers.  
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2.1.3 Genetic polymorphism in UGTs 
Many human UGT enzymes were found to be genetically polymorphic. The mutations in 
UGT1A1 gene result in several syndromes connected with decreased bilirubin detoxification 
capacity of UGT1A1. Kadakol et al. (2000) summed up data about more than 50 mutations of 
UGT1A1 causing Crigler–Najjar syndrome type I and type II. Patients suffering from type I, 
also called congenital familial nonhemolytic jaundice with kernicterus, completely lack the 
UGT1A1 enzymatic activity resulting in toxic effects of bilirubin on the central nervous 
system. The most common deficiency of UGT1A1 enzyme is Gilbert‘s syndrome. 2–12% of 
the population suffer from this benign disorder characterized by intermittent unconjugated 
hyperbilirubinemia. In most cases, this syndrome is caused by a mutation in the promotor 
region of UGT1A1 gene (Monaghan et al., 1996). Increased toxicity of a pharmacologically 
active metabolite of irinotecan (SN–38) has been described in patients suffering from 
Gilbert’s syndrome as UGT1A1 is the main enzyme responsible for the formation of the 
inactive SN–38 glucuronide (Wasserman et al., 1997). The genetic variability in the UGT1 or 
UGT2 gene families was also suggested to alter risk of cancer either as a result of decreased 
inactivation of hormones such as estrogens or due to reduced detoxification of 
environmental carcinogens and their reactive metabolites (Guillemette, 2003). 
2.2 Sulfoconjugation 
Sulfoconjugation (or sulfonation) constitutes an important pathway in the metabolism of 
numerous both exogenous and endogenous compounds. The sulfonation reaction was first 
recognized by Baumann in 1876. Baumann detected phenyl sulfate in the urine of a patient 
who had been administered phenol. The sulfonation reactions are mediated by a supergene 
family of enzymes called sulfotransferases (SULTs). In general, these enzymes catalyze the 
transfer of sulfonate (SO3–) from the universal sulfonate donor 3‘–phosphoadenosine 5‘–
phosphosulfate (PAPS) to the hydroxyl or amino group of an acceptor molecule, Fig. 2. The 
incorrect term sulfation is sometimes used since sulfated products are formed in this type of 
reactions. PAPS is a universal donor of sulfonate moiety in sulfonation reactions and has 
been shown to by synthesized by almost all tissues in mammals from inorganic sulfate 
(Klaassen & Boles, 1997). Depletion of PAPS due to lack of inorganic sulfate or due to 
genetic defects of enzymes participating in PAPS synthesis may lead to reducing of 
sulfonation capacity which could affect the metabolism of xenobiotics or disrupt the 
equilibrium between synthesis and degradation of active endogenous compounds. 
To date, two large groups of SULTs have been identified. The first group includes 
membrane–bound enzymes with no demonstrated xenobiotic–metabolising activity. These 
enzymes are localized in the Golgi apparatus and they are involved in metabolism of 
endogenous peptides, proteins, glycosaminoglycans, and lipids (Habuchi, 2000). Cytosolic 
SULTs constitute the second group of sulfotransferases and play a major role in conjugation 
of a broad spectrum of xenobiotics including environmental chemicals, natural compounds, 
drugs (Gamage et al., 2006) as well as endogenous compounds such as steroid hormones, 
iodothyronines, catecholamines, eicosanoids, retinol or vitamin D (Glatt & Meinl, 2004). 
Moreover, cytosolic SULTs are presumed to play a crucial role in the detoxification 
processes occurring in the developing human fetus since no UGTs transcripts have been 
detected in fetal liver at 20 weeks of gestation (Strassburg et al., 2002). Sulfonation is 
generally described as a detoxification pathway for many xenobiotics. Addition of the 
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sulfonate moiety to the molecule of a parent compound or most often to the molecule of its 
metabolite originating in the oxidative phase of drug metabolism leads to formation of a 
water–soluble compound which is then easily eliminated from the body. However, in 
several cases the sulfonation reaction can lead to formation of a more active metabolite 
compared to the parent compound as is the case for the hair follicle stimulant minoxidil 
(Buhl et al., 1990) or the diuretic agent triamterene (Mutschler et al., 1983). Furthermore, the 
role of sulfotransferases in the activation of various procarcinogens and promutagens was 
confirmed (Gilissen et al., 1994).  
 
Fig. 2. The formation of sulfates (R–O–SO3– ) and sulfamates (R1–NR2–SO3– ). These reactions 
are catalyzed by 3‘–phosphoadenosine 5‘–phosphosulfate (PAPS)–dependent 
sulfotransferases. 
2.2.1 Human forms of cytosolic SULTs and tissue distribution 
In the following text we will focus only on cytosolic sulfotransferases, since this enzyme 
superfamily plays a key role in the biotransformation of multiple xenobiotics as well as 
endogenous substrates. Recently, a nomenclature system for the superfamily of cytosolic 
SULTs has been established analogously to those of other drug metabolising enzymes such 
as cytochromes P450 or UDP–glucuronosyltranferases (Blanchard et al., 2004). The 
superfamily of cytosolic sulfotransferases is subsequently divided into families and 
subfamilies according to the amino acid sequence identity among individual SULTs. In 
detail, members of one SULTs family share at least 45% amino acid sequence identity, 
whereas SULTs subfamily involves individual members with at least 60% identity. To date, 
four human SULT families, SULT1, SULT2, SULT4 and SULT6, have been identified. These 
SULT families include at least 13 different members. The SULT1 family comprises of 9 
members divided into 4 subfamilies (1A1, 1A2, 1A3, 1A4, 1B1, 1C1, 1C2, 1C3 and 1E1). 
SULT2A (SULT2A1) and SULT2B (SULT2B1a and SULT2B1b) belong to SULT2 family. The 
SULT4A1 and SULT6B1 are the only members of the SULT4 and SULT6 family, respectively 
(Lindsay et al., 2008). Cytosolic sulfotransferases exert relatively broad tissue distribution. 
The members of SULT1A family were found in liver, brain, breast, intestine, jejunum, lung, 
adrenal gland, endometrium, placenta, kidney and in blood platelets. Figure 3 displays 
SULT expression “pies“ of the most important human cytosolic transferases in human 
tissues. SULT1A1 is predominantly expressed in the liver (Hempel et al., 2007). In contrast 
to SULT1A1, the SULT1A3 enzyme was not detected in human adult liver. SULT1B1 has 
been found in liver, small intestine, colon, and leukocytes (Wang et al., 1998). Members of 
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SULT1C subfamily were identified in fetal human tissues such as liver (Hehonah et al., 1999) 
or lung and kidney (Sakakibara et al., 1998) as well as in adult human stomach (Her et al., 
1997). The predominant expression of SULT1E1 was found in human liver and jejunum 
(Riches et al., 2009). Major sites of SULT2A1 expression are the liver, adrenal gland, ovary, and 
duodenum (Javitt et al., 2001). Members of SULT2B subfamily are localized in human prostate, 
placenta, adrenal gland, ovary, lung, kidney, and colon (Glatt & Meinl, 2004). Recently, an 
exclusive localization of human SULT4A1 in the brain was confirmed (Falany et al., 2000).  
 
Fig. 3. The human SULT “pies”. The mean expression values for each enzyme are displayed 
as percentages of the total sum of immunoquantified SULTs (maximum five enzymes) 
present in each tissue. Expression values are shown for liver (A), small intestine (B), kidney 
(C), and lung (D) (Riches et al., 2009). 
2.2.2 Substrates of SULTs 
SULT1A1 has been shown to be one of the most important sulfotransferases participating in 
metabolism of xenobiotics in humans. It has also been termed phenol sulfotransferase (P–
PST) or thermostable phenol sulfotransferase (TS PST1). In general, SULT1A1 is responsible 
for sulfoconjugation of phenolic compounds such as monocyclic phenols, naphtols, benzylic 
alcohols, aromatic amines or hydroxylamines (Glatt & Meinl, 2004). Acetaminophen, 
minoxidil as well as dopamine or iodothyronines undergo sulfonation by SULT1A1. 
SULT1A1 also takes part in transformation of hydroxymethyl polycyclic aromatic 
hydrocarbons, N–hydroxyderivatives of arylamines, allylic alcohols and heterocyclic amines 
to their reactive intermediates which are able to bind to nucleophilic structures such as DNA 
and consequently act as mutagens and carcinogens (Glatt et al., 2001). SULT1A2 also plays 
an important role in the toxification of several aromatic hydroxylamines (Meinl et al., 2002). 
SULT1A3, formerly known as thermolabile phenol SULT (TL PST) or monoamine 
sulfotransferase, exhibits high affinity for catecholamines (dopamine) and contributes to the 
regulation of the rapidly fluctuating levels of neurotransmitters. The human SULT1B1 was 
isolated and described by Fujita et al. (1997) and was shown to be the most important 
sulfotransferase in thyroid hormone metabolism. SULT1E1 plays a key role in estrogen 
homeostasis. This enzyme conjugates 17ǃ–estradiol and other estrogens in a step leading to 
their inactivation. Since 17ǃ–estradiol and relative compounds regulate various processes 
occurring in humans, inactivation of these compounds by the SULT1E1 enzyme constitute 
an important step in the prevention and development of certain diseases. Down regulation 
or loss of SULT1E1 could be to a certain extent responsible for growth of tumor in hormone 
sensitive cancers such as breast or endometrial cancer (Cole et al., 2010). SULT2A and 
SULT2B subfamilies include the hydroxysteroid sulfotransferases with partially overlapping 
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substrate specifities. SULT2A1 is also termed as dehydroepiandrosterone sulfotransferase 
(DHEA ST) and conjugates various hydroxysteroids such as DHEA, androgens, bile acids 
and oestrone (Comer et al., 1993). Recently, a role of SULT2A1 in metabolism of quinolone 
drugs in humans was confirmed (Senggunprai et al., 2009). Clinically relevant substrates for 
other cytosolic sulfotransferases have not been identified yet. 
2.2.3 Genetic polymorphisms in SULTs 
Genetic polymorphism was detected in many SULT forms such as the SULT1A1, SULT1A3, 
SULT1C2, SULT2A1, SULT2A3 and SULT2B1 enzyme (Lindsay et al., 2008). Single 
nucleotide polymorphism in the SULT1A1 gene leading to an Arg213 → His amino acid 
substitution is relatively frequent in the Caucasian population (25.4–36.5%) (Glatt & Meinl, 
2004). This mutation results in a variation of SULT1A1 thermal stability and enzymatic 
activity. Several authors have claimed that SULT1A1 polymorphism might play a role in the 
pathophysiology of lung cancer (Arslan et al., 2009), urothelial carcinoma (Huang, 2009), 
and meningiomal brain tumors (Bardakci, 2008). 
2.3 Glutathione S–conjugation 
Since the first detection of glutathione transferase activity in rat liver cytosol by Booth in the 
early 1960s, the family of glutathione transferases (synonymously glutathione S–
transferases; GSTs) has been studied in detail. Undoubtedly, the members of glutathione 
transferase family play an important role in metabolism of certain therapeutics, 
detoxification of environmental carcinogens and reactive intermediates formed from various 
chemicals by other xenobiotic–metabolising enzymes. Furthermore, GSTs constitute an 
important intracellular defence against oxidative stress and they appear to be involved in 
synthesis and metabolism of several derivatives of arachidonic acid and steroids (van 
Bladeren, 2000). On the other hand, various chemicals have been shown to be activated into 
potentially dangerous compounds by these enzymes (Sherratt et al., 1997). In general, these 
enzymes catalyze a nucleophilic attack of reduced glutathione on lipophilic compounds 
containing an electrophilic atom (C–, N– or S–). In addition to nucleophilic substitutions, 
these transferases also account for Michael additions, isomerations, and hydroxyperoxide 
reductions. In most cases, more polar glutathione conjugates are eliminated into the bile or 
are subsequently subjected to other metabolic steps eventually leading to formation of 
mercapturic acids. Figure 4 shows the sequential steps in the synthesis of mercapturic acids. 
Mercapturic acids are excreted from the body in urine (Commandeur et al., 1995). For 
instance, industrial chemicals such as acrylamide or trichloroethylene are detoxified via 
mercapturic acids (Boettcher et al., 2005; Popp et al., 1994).  
2.3.1 Differentiation of GSTs, their cellular localization and tissue distribution 
Up to now, two different superfamilies of GSTs have been described. The first one includes 
soluble dimeric enzymes localized mainly in cytosole but certain members of this 
superfamily have been also identified in mitochondria (Robinson et al., 2004) or in 
peroxisomes (Morel et al., 2004). The superfamily of human soluble GSTs is further divided 
into eight separate classes: Alpha (A1–A4), Kappa (K1), Mu (M1–M5), Pi (P1), Sigma (S1), 
Theta (T1–T2), Zeta (Z1) and Omega (O1–O2) (Hayes et al., 2005). Microsomal GSTs 
designated as the membrane associated proteins in eicosanoid and glutathione metabolism 
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(MAPEG) consitute the second family of human GSTs. The human MAPEG superfamily 
includes six members: 5–lipoxygenase activating protein (FLAP), leukotriene C4 synthase 
(both involved in leukotriene synthesis), MGST1, MGST2, MGST3 (GSTs as well as 
glutathione dependent peroxidases) and prostaglandin E synthase (PGES) (Bresell et al., 
2005). Both the soluble GSTs and MAPEG exhibit a broad tissue distribution; being found in 
liver, kidney, brain, lung, heart, pancreas, small intestine, prostate, spleen, and skeletal 
muscles (Hayes & Strange, 2000). 
 
Fig. 4. Formation of mercapturic acid. Glutathione S–transferase (1) catalyzes the conjugation 
between glutathione and various endogenous or xenobiotic electrophilic compounds. 
Subsequently, the resulting glutathione S–conjugate is broken down to a cysteine  
S–conjugate by Ǆ-glutamyltranspeptidase (2) and dipeptidases (3). Finally, cysteine  
S–conjugate N–acetyltransferase (4) catalyses formation of mercapturic acid. 
2.3.2 Substrates of human GSTs 
Various electrophilic compounds act as substrates for GSTs. They include a broad spectrum of 
ketones, quinones, sulfoxides, esters, peroxides, and ozonides (van Bladeren et al., 2000). 
Chemotherapeutics (such as busulfan, cis–platin, ethacrynic acid, cyclophosphamide, 
thiotepa); industrial chemicals, herbicides, pesticides (acrolein, lindane, malathion, tridiphane) 
are detoxified by GSTs (Hayes et al., 2005). Epoxides and other reactive intermediates formed 
from environmental procarcinogens mostly as a result of metabolism by cytochromes P450 
(aflatoxin B1, polycyclic aromatic hydrocarbons, styrene, benzopyrene, heterocyclic amines) 
also undergo detoxification by soluble GSTs. Besides their enzymatic activity, cytosolic GSTs 
(such as class Alpha) exhibit an ability to bind various hydrophobic ligands (xenobiotics as 
well as hormones) and thus contribute to their intracellular transport and disposition. GSTs 
play an essential role in the fight against products of oxidative stress which unavoidably 
damage cell membrane lipids, DNA, or proteins. Reactive intermediates resulting from lipid 
peroxidation (4–hydroxynonenal), nucleotide peroxidation (adenine propenal) or 
catecholamine peroxidation (aminochrome, dopachrome, adrenochrome) are particularly 
inactivated by GSTs (Dagnino–Subiabre et al., 2000). Several specific substrates for GSTs have 
been identified. For instance, ethacrynic acid has been found to be predominantly metabolised 
by GSTP1, whereas trans–stilbene oxide is a specific substrate for GSTM1 (van Bladeren, 2000). 
The GSTT1 enzyme is responsible for conjugation of halogenated organic compounds such as 
dichlormethane or ethylene–dibromide (Landi, 2000). This step leads to activation of these 
compounds to their reactive electrophilic metabolites with potential mutagenic and 
cancerogenic effect. Ethylene–dibromide, a gasoline additive and a fumigant, is presumed to 
be potential human carcinogen because it is transformed by GSTs to DNA–reacting 
episulfonium ion (van Bladeren, 2000). The glucocorticoid response element and the xenobiotic 
response element activated by glucocorticoids and planar aromatic hydrocarbons respectively 
might play a role in the induction of expression of GSTs (Talalay et al., 1988). 
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2.3.3 Genetic polymorphism in GSTs 
Most members of both glutathione transferase superfamilies have been found to be genetically 
polymorphic. Several genetic variants of particular GSTs are supposed to contribute to the 
development of certain cancers or other diseases. Furthermore, genetic polymorphism in GSTs 
is pressumed to influence metabolism and disposition of various anticancerogenic drugs 
(Crettol et al., 2010). GSTP1 is responsible for metabolism of alkylating agents, topoisomerase 
inhibitors, antimetabolites, or tubulin inhibitors used in treatment of cancer. The common 
allele GSTP1*A is cytoprotective against the toxic effects of chemotherapeutics, whereas the 
functionally less competent allele GSTP1*B is thought to increase the toxicity of 
anticancerogenic drugs in patients with this gene variant due to decreased metabolic activity 
of impaired enzyme. Cyclophosphamide is biotransformed by GSTA1. Defective GSTA1*B 
allele was associated with increased survival in breast cancer patients treated with 
cyclophosphamide (Sweeney et al., 2003). On the other hand, several drugs activated by GSTs 
require a well–functioning enzyme. Patients with the active GSTM1 gene treated for acute 
myeloid leukemia with doxorubicin had a superior survival rate compared to patients with at 
least one null allele (Autrup et al., 2002). Individuals with lacking functional GSTM1, GSTT1, 
and GSTP1 have been shown to have a higher incidence of bladder, breast, colorectal, 
head/neck, and lung cancer. Genetically–based defects of these enzymes are also noteworthy 
because of their partial responsibility for increased risk of asthma, allergies, atherosclerosis, 
and rheumatoid arthritis (van Bladeren, 2000; Hayes et al., 2005). 
2.4 Acetylation 
Compared to sulfonations and glucuronidations, acetylations are modest in terms of the 
number and variety of substrates, but remain significant in a toxicological perspective. 
Drugs and other foreign compounds that are acetylated in intact animals are either aromatic 
amines or hydrazines, which are converted to aromatic amides and aromatic hydrazides 
(Parkinson, 2001). Acetylation reactions are characterized by the transfer of an acetyl moiety, 
the donor generally being acetyl coenzyme A, while the accepting chemical group is 
a primary amino function. As far as xenobiotic metabolism is concerned, three general 
reactions of acetylation have been documented, namely N– (Fig. 5a, b), O– (Fig. 5c), and 
N,O–acetylations (Fig. 5d). N–acetylation of aromatic amine is recognized as a major 
detoxification pathway in arylamine metabolism in experimental animals and humans 
(Hein et al., 2000). However, O– and N,O–acetylations occur in alternative metabolic 
pathways following activation by N–hydroxylation. The resulting N–acetoxyarylamines are 
highly unstable, spontaneously forming arylnitrenium ions that bind to DNA (Bland & 
Kadlubar, 1985) and ultimately lead to mutagenesis and carcinogenesis (Kerdar et al., 1993). 
2.4.1 N–Acetyltransferases 
In humans, acetylation reactions are catalyzed by two N–acetyltransferase isoenzymes 
(NATs), N–acetyltransferase 1 (NAT1) and 2 (NAT2). NATs are cytosolic enzymes found in 
many tissues of various species. The human NAT1 and NAT2 genes are located on 
chromosome 8 pter–q11, and share 87% coding sequence homology (Blum et al., 1990). 
NAT1 and NAT2 have distinct substrate specificities and differ markedly in terms of organ 
and tissue distribution. NAT2 protein is present mainly in the liver (Grant et al., 1990) and 
intestine (Hickman et al., 1998). NAT1 appears to be ubiquitous. Expression of human NAT1  
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Fig. 5. Reactions catalysed by N–acetyltransferases. (a,b) N–acetylation of arylamine and 
arylhydrazine, (c) O–acetylation of N–arylhydroxylamine, (d) N, O–acetyltransfer of an N–
hydroxamic acid. These reactions use acetyl–coenzyme A as acetyl donor. 
has been detected in adult liver, bladder, digestive system, blood cells, placenta, skin, 
skeletal muscles, gingiva (Dupret & Lima, 2005), mammary tissue, prostate, and lung by a 
number of methods (Sim et al., 2008). A notable difference between the two isoenzymes is 
the presence of NAT1 activity in fetal and neonatal tissue, such as lungs, kidneys, and 
adrenal glands (Pacifici et al., 1986). By contrast, NAT2 is not evident until about 12 months 
after birth (Pariente–Khayat et al., 1991). NAT1 has also been detected in cancer cells, in 
which it may not only play a role in the development of cancers through enhanced 
mutagenesis but may also contribute to the resistance of some cancers to cytotoxic drugs 
(Adam et al., 2003). NATs are involved in the metabolism of a variety of different 
compounds to which we are exposed on a daily basis. In humans, acetylation is a major 
route of biotransformation for many arylamine and hydrazine drugs, as well as for a 
number of known carcinogens present in diet, cigarette smoke, car exhaust fumes, and 
environment in general. Human NAT1 and human NAT2 have distinct but overlapping 
substrate profiles and also have specific substrates which can be used as ”probe“ substrates 
for each particular isoenzyme. Substrates of NAT1 include p–aminobenzoic acid, p–
aminosalicylic acid, the bacteriostatic antibiotics sulfamethoxazole and sulfanilamide, 2–
aminofluorene and caffeine (Ginsberg et al., 2009). Moreover, it has been proposed by 
Minchin that human NAT1 plays a role in folate metabolism through the acetylation of the 
folate metabolite p–aminobenzoylglutamate (Minchin, 1995). Human NAT2 is a xenobiotic–
metabolising enzyme that provides a major route of detoxification of drugs such as isoniazid 
(an anti–tuberculotic drug), hydralazine and endralazine (anti–hypertensive drugs), a 
number of sulphonamides (anti–bacterial drugs) (Kawamura et al., 2005), procainamide 
(anti–arrhythmic drug), aminoglutethimide (an inhibitor of adrenocortical steroid 
synthesis), nitrazepam (a benzodiazepine) and the anti–inflammatory drug dapsone 
(Ginsberg et al., 2009; Butcher at al., 2002). Both NAT1 and NAT2 are polymorphic enzymes, 
with 28 NAT1 and 64 NAT2 alleles having been identified to date (see 
http://louisville.edu/medschool/pharmacology/NAT.html for details of alleles; last 
update May 24, 2011). N–acetylation polymorphism represents one of the oldest and most 
intensively studied pharmacogenetic traits and refers to hereditary differences concerning 
the acetylation of drugs and toxicants. The genetic polymorphism in NAT activity was first 
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recognised in tuberculosis patients treated with isoniazid, which is metabolised principally by 
N–acetylation. The polymorphism causes individual differences in the rate of metabolism of 
this drug. Individuals with a faster rate are called rapid acetylators and individuals with a 
slower rate are called slow acetylators. Rapid acetylators were competent in isoniazid 
acetylation but the drug was cleared less efficiently in the slow acetylator group, which 
resulted in elevated serum concentration and led to adverse neurologic side effects due to an 
accumulation of unmetabolized drug (Brockton et al., 2000). Consistent with the toxicity of 
isoniazid in slow acetylators, there is an increased incidence of other drug toxicities in subjects 
carrying defective NAT2 alleles, such as lupus erythematosus in patients treated with 
hydralazine or procainamide (Sim et al., 1988), and haemolytic anemia and inflammatory 
bowel disease after treatment with sulfasalazine (Chen et al., 2007). The high frequency of the 
NAT2 and also NAT1 acetylation polymorphism in human population together with 
ubiquitous exposure to aromatic and heterocyclic amines suggest that NAT1 and NAT2 
acetylator genotypes are important modifiers of human cancer susceptibility. Many studies 
suggested a relationship between acetylation phenotypes (in particular, arising from NAT2 
genotypes) and the risk of various cancer including colorectal, liver, breast, prostate, head and 
neck (Agúndez, 2008) and other disease conditions such as birth defects (Lammer et al., 2004) 
or neurodegenerative and autoimmune diseases (Ladero, 2008).  
2.5 Methylation 
Methylation is a common but generally minor pathway of xenobiotic biotransformation. 
Unlike most other conjugative reactions, methylation often does not dramatically alter the 
solubility of substrates and results either in inactive or active compounds. Methylation 
reactions are primarily involved in the metabolism of small endogenous compounds such as 
neurotransmitters but also play a role in the metabolism of macromolecules for example 
nucleic acids and in the biotransformation of certain drugs. A large number of both 
endogenous and exogenous compounds can undergo N– (Fig. 6a), O– (Fig. 6b), S– (Fig. 6c) 
and arsenic–methylation during their metabolism (Feng et al., 2010). The co–factor required 
to form methyl conjugates is S–adenosylmethionine (SAM), which is primarily formed by 
the condensation of ATP and L–methionine. 
 
Fig. 6. Methylation reactions catalyzed by methyltransferases.  
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2.5.1 N–methylation 
Several N–methyltransferases have been described in humans and other mammals; 
including indolethylamine N–methyltransferase (INMT), which catalyzes the N–methylation of 
tryptamine and structurally related compounds. The INMT exhibits wide tissue 
distribution. Human INMT was expressed in the lung, thyroid, adrenal gland, heart, and 
muscle but not in the brain (Thompson et al., 1999). Since INMT is predominantly present in 
peripheral tissues, its main physiological function is presumably non–neural. Nicotinamide 
N–methyltransferase (NNMT) is a SAM–dependent cytosolic enzyme that catalyzes the N–
methylation of nicotinamide, pyridines, and other structural analogues. NNMT is 
predominantly expressed in the liver; expression has been also reported in other tissues 
such as the kidney, lung, placenta, and heart (Zhang et al., 2010). Several N–methylated 
pyridines are well–established dopaminergic toxins and the NNMT can convert pyridines 
into toxic compounds (such as 4–phenylpyridine into N–methyl–4– phenylpyridinium ion 
[MPP+]). NNMT has been shown to be present in the human brain, a necessity for 
neurotoxicity, because charged compounds cannot cross the blood–brain barrier (Williams 
& Ramsden, 2005). NNMT was one of the potential tumor biomarkers identified in a wide 
range of tumors such as thyroid, gastric, colorectal, renal, and lung cancer (Zhang et al., 
2010). Histamine N–methyltransferase (HNMT), the second most important histamine 
inactivating enzyme, is a cytosolic enzyme specifically methylating the imidazole ring of 
histamine and closely related compounds in the intracellular space of cells. Levels of HNMT 
activity in humans are regulated genetically. HNMT is widely expressed in human tissues; 
the greatest expression is in the liver and kidney, but also in the spleen, colon, prostate, ovary, 
brain, bronchi, and trachea (Maintz & Novak, 2007). Common genetic polymorphisms for 
HNMT might be related to a possible role for individual variation in histamine metabolism in 
the pathophysiology of diseases such as allergy, asthma, peptic ulcer disease, and some 
neuropsychiatric illnesses (Preuss et al., 1998). Phenylethanolamine N–methyltransferase (PNMT) 
plays a role in neuroendocrine and blood pressure regulation in the central nervous system. 
PNMT, the terminal enzyme of the catecholamine biosynthesis pathway, catalyzes the N–
methylation of the neurotransmitter norepinephrine to form epinephrine (Ji et al., 2005). 
PNMT is a cytosolic enzyme that is present in many tissues throughout the body, with 
particularly high concentration in the adrenal medulla, adrenergic neurons in the amygdala 
and retina and the left atrium of the heart (Haavik et al., 2008). Its activity increases after stress 
in response to glucocorticoids and neuronal stimulation (Saito et al., 2001). Several studies 
have suggested that two common PNMT promoter single nucleotide polymorphisms might be 
associated with risk of diseases such as essential hypertension, early–onset Alzheimer’s 
disease, or multiple sclerosis (Ji et al., 2008). Phosphatidylethanolamine N–methyltransferase 
(PEMT) converts phosphatidylethanolamine to phosphatidylcholine in mammalian liver. 
Phosphatidylcholine is nutrient critical to many cellular processes such as phospholipid 
biosynthesis, lipid–cholesterol transport, or transmembrane signaling. The human PEMT gene 
encodes for two isoforms of the enzyme, namely PEMT1, which is localized in the 
endoplasmic reticulum and generating most of the PEMT activity, and PEMT2, a liver specific 
isoform exclusively localized in mitochondria–associated membranes (Tessitore et al., 2003). 
2.5.2 O–methylation 
The process of O–methylation of phenols and catechols is catalyzed by two different 
enzymes known as phenol O–methyltransferase and catechol O–methyltransferase. Phenol 
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O–methyltransferase (POMT) is an enzyme that transfers the methyl group of SAM to phenol to 
form anisole. POMT is a localized in the microsomes of the liver and lungs of mammals but is 
also present in other tissues. Catechol O–methyltransferase (COMT) is a magnesium–dependent 
enzyme which was first described by Axelrod in 1957. It is an enzyme that plays a key role in 
the modulation of catechol–dependent functions such as cognition, cardiovascular function, 
and pain processing. COMT is involved in the inactivation of catecholamine neurotransmitters 
such as epinephrine, norepinephrine, and dopamine, but also catecholestrogens and catechol 
drugs such as the anti–Parkinson´s disease agent L–DOPA and the anti–hypertensive 
methyldopa (Weinshilboum et al., 1999). Two forms of human COMT have been identified, a 
cytoplasmic soluble form (S–COMT) and a membrane–bound form (MB–COMT) located in the 
cytosolic side of the rough endoplasmic reticulum The S–COMT is predominantly expressed 
in the human liver, intestine and kidney (Taskinen et al., 2003), whereas the membrane–bound 
form is more highly expressed in all regions of the human central nervous system (Tunbridge 
et al., 2006). A common functional polymorphism at codons 108 and 158 in the genes coding 
for S–COMT and MB–COMT (COMT Val 108/158 Met), respectively, has been examined in 
relationship to a number of neurological disorders involving the noradrenergic or 
dopaminergic systems, such as schizophrenia (Park et al., 2002) or Parkinson's disease (Kunugi 
et al., 1997). It has also been suggested that a common functional genetic polymorphism in the 
COMT gene may contribute to the etiology of alcoholism (Wang et al., 2001).  
2.5.3 S–methylation 
Thiol methylation is important in the metabolism of many sulfhydryl drugs. Human tissues 
contain two separate genetically regulated enzymes that can catalyze thiol S–methylation. 
Thiol methyltransferase (TMT) is a membrane–bound enzyme that preferentially catalyzes the 
S–methylation of aliphatic sulfhydryl compounds such as captopril and D–penicillamine, 
whereas thiopurine S–methyltransferase (TPMT) is a cytoplasmic enzyme that preferentially 
catalyzes the S–methylation of aromatic and heterocyclic sulfhydryl compounds including 
anticancer and immunosuppressive thiopurines such as 6–mercaptopurine, 6–thioguanine, 
and azathioprine. Thiopurine drugs have a relatively narrow therapeutic index and are 
capable of causing life–threatening toxicity, most often myelosuppression (Sahasranaman et 
al., 2008). TPMT genetic polymorphism represents a striking example of the clinical 
importance of pharmacogenetics. In 2010, 29 different variant TPMT alleles have been 
described (Ford & Berg, 2010) and this may be associated with large interindividual 
variations in thiopurine drug toxicity and therapeutic efficacy. Allele frequencies for genetic 
polymorphism are such that ~1 in 300 Caucasians is homozygous for a defective allele or 
alleles for the trait of very low activity, ~11% of people are heterozygous and have 
intermediate activity. Subjects homozygous for low TPMT activity have a high risk of 
myelosuppression after treatment with standard dose of azathioprine. Generally, TPMT–
deficient patients (homozygous mutant) can be treated with 6–10% of the standard dose of 
thiopurines (Zhou, 2006). TPMT shows the highest level of expression in liver and kidney 
and the physiological role of this enzyme, despite extensive investigation, remains unclear. 
2.5.4 As–methylation 
Arsenic is a well–known naturally occurring metaloid which is considered as a multiorgan 
human carcinogen. Occupational exposure to arsenic occurs in the smelting industry and 
www.intechopen.com
 Topics on Drug Metabolism 
 
48
during the manufacture of pesticides, herbicides, and other agricultural products. Arsenic 
plays a dual role as environmental carcinogenic pollutant and as a successful anticancer 
drug against promyelocytic leukemia (Wood et al., 2006). Its metabolism proceeds via a 
complicated enzymatic pathway, acting both as detoxification and producing more toxic 
intermediates. Methylation is an important reaction in the biotransformation of arsenic. 
Liver is considered to be the primary site for the methylation of inorganic arsenic (iAs) and 
arsenic (+3 oxidation state) methyltransferase (AS3MT) is shown to be critical specifically for the 
arsenic metabolism, and thus may be pharmacologically important as well. Methylated and 
dimethylated arsenic are the major urinary metabolites in human and many other species 
(Li et al., 2005). Two reaction schemes (Fig. 7) have been developed to describe the 
individual steps in the enzymatically catalysed conversion of iAs to methylated metabolites 
(Thomas, 2007). Although pentavalent methylated arsenicals (MAsV, DMAsV, TMAsV) are 
less toxic than inorganic ones (iAsV, iAsIII), the trivalent intermediated formed during the 
methylation process (MAsIII, DMAsIII) are much more cytotoxic and genotoxic (Hughes, 
2009). 
 
Fig. 7. Alternative schemes for the conversion of inorganic arsenic (iAs) into methylated 
metabolites. (a) Scheme for the oxidative methylation of arsenicals in which reduction of 
oxidized arsenicals is interposed between each methylation reaction. (b) Scheme for 
methylation of arsenic involving formation of arsenic–glutathione (GSH) complex. SAM, S–
adenosylmethionine; SAH, S–adenosylhomocysteine (According to Thomas, 2007). 
Several single nucleotide polymorphisms in exons and introns in this gene are reported to 
be related to inter–individual variation in the arsenic metabolism (Fujihara et al., 2010). 
Polymorphism in AS3MT may influence arsenic metabolism and potentially susceptibility to 
its toxic and carcinogenic effects. 
2.6 Amino acid conjugation reactions 
The first description of glycine conjugation was published in 1842 by Keller. Xenobiotics 
containing a carboxyl group (–COOH) are widely used as drugs (for example simvastatin, 
valproic acid, or acetylsalicylic acid), herbicides, insecticides, and food preservatives. In 
addition, many xenobiotics are readily metabolized to carboxylic acids which may then be 
conjugated with amino acids. The ability of xenobiotics to undergo amino acid conjugation 
depends on the steric hindrance around the carboxylic acid group, and on substituents of 
the aromatic ring or aliphatic side chain. Amino acid conjugation is the most important 
route of detoxification, not only for many xenobiotic carboxylic acids but also for 
endogenous acids. It is known that amino acid conjugation of exogenous carboxylic acids 
occurs in a two–step process (Reilly et al., 2007). Amino acids conjugation of carboxylic acids 
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is a special form of acetylation and leads to amide bond formation. The most common 
amino acid in such reactions is glycine, and its prototypical substrate is benzoic acid, more 
precisely its benzoyl–CoA cofactor (Fig. 8). Bile acids are also conjugated by a similar 
sequence of reactions involving a microsomal cholyl–CoA synthetase and a cytosolic 
enzyme bile acid–CoA: amino acid N–acyltransferase (Falany et al., 1994). In relation to 
xenobiotic carboxylic acids, amino acid conjugation involves enzymes located principally in 
the mitochondria of liver and kidney while conjugation of bile acids is extramitochondrial, 
involving enzymes located in the endoplasmic reticulum and peroxisomes (Reilly et al., 
2007; Knights et al., 2007).  
 
Fig. 8. Conjugation of a xenobiotic with amino acid, formation of hippuric acid. 
Glycine and glutamate appear to be the most common acceptors of amino acids in 
mammals. In humans, more than 95% of bile acids are N–acyl amidates with glycine or 
taurine. Although products of amino acid conjugation are considered to be metabolically 
stable and nontoxic, it has been suggested that the first reaction of amino acid conjugation 
leads in some cases to formation of potentially toxic intermediates. This toxification 
pathway involves conjugation of N–hydroxy aromatic amines with the carboxylic acid 
group of serine and proline. Amino acid activated by aminoacyl–tRNA–synthetase (Fig. 9) 
subsequently reacts with an aromatic hydroxylamine to form N–ester that can degrade to 
produce a reactive nitrenium ion (Parkinson, 2001). In general, the toxicity of nitrenium ions 
is clinically relevant since these electrophiles possesing DNA–binding ability are responsible 
for carcinogenicity of aromatic amines. 
 
Fig. 9. Conjugation of a xenobiotic with amino acid, formation of electrophilic nitrenium ion. 
3. Conclusion 
Xenobiotic biotransformation is a key mechanism for maintaining homeostasis during 
exposure to various xenobiotics, such as drugs, industrial chemicals, or food 
procarcinogens. In humans and other mammals, the liver is the major site of expression of 
xenobiotic–metabolising enzymes, but extrahepatically localized enzymes also appear to be 
of great importance. In the intestine for example, several drug metabolising enzymes are 
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presumed to decrease the bioavailability of orally administered drugs or to activate 
environmental carcinogens. Phase II of metabolism may or may not be preceded by Phase I 
reactions. Phase II enzymes undoubtedly play an important role in the detoxification of 
various xenobiotics. Furthermore, they significantly contribute to maintaining of 
homeostasis by binding, transport or inactivation of biologically active compounds such as 
hormones, bile acids, or other mediators. In contrast to their beneficial effects, these 
enzymes also participate in formation of reactive intermediates of various compounds. The 
most–discussed example of toxification reactions is the conjugation of N–hydroxy aromatic 
amines. These compounds undergo activation to toxic metabolites by numerous reactions, 
including N–glucuronidation by UGTs, O–acetylation by NATs, O–sulfonation by SULTs, 
and conjugation with amino acids by aminoacyl–tRNA–synthetase. The newly formed 
reactive electrophilic nitrenium and carbonium ions can act as carcinogens and mutagens 
due to covalent binding to DNA or to other biomolecules. Genetic polymorphisms of Phase 
II enzymes is another noteworthy issue. Impaired metabolism of drugs due to genetically 
based dysfunction of competent enzymes may lead to manifestation of toxic effects of 
clinically used drugs. Moreover, it is evident that genetic polymorphisms in these enzymes 
are responsible for the developement of a number of neurological disorders or cancers. In 
conclusion, Phase II enzymes are an interesting research field since they play an essential 
role in the metabolism of hundreds of foreign compounds as well as in regulation of 
metabolism and disposition of various endogenous biologically active substances and thus 
maintaining homeostasis in the human body.  
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